Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Wide moat ASX share beats earnings guidance
stocks
Cheap with attractive yield: Fair Value lifted for retail REIT after earnings
stocks
Cheap ASX share may have more room to run
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,447.10 | 21.30 | 0.23% |
| CAC 40 | 8,726.03 | 11.10 | 0.13% |
| DAX 40 | 26,323.88 | 4.43 | 0.02% |
| Dow JONES (US) | 53,975.98 | 60.95 | -0.11% |
| FTSE 100 | 10,862.50 | 38.59 | -0.35% |
| HKSE | 26,040.17 | 102.68 | 0.40% |
| NASDAQ | 26,605.36 | 85.26 | -0.32% |
| Nikkei 225 | 66,970.22 | 1,363.51 | 2.08% |
| NZX 50 Index | 13,844.62 | 43.62 | -0.31% |
| S&P 500 | 7,753.11 | 4.53 | -0.06% |
| S&P/ASX 200 | 9,256.50 | 19.70 | 0.21% |
| SSE Composite Index | 3,953.44 | 13.15 | -0.33% |